DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
37 hedge funds and large institutions have $9.99M invested in DMK Pharmaceuticals Corporation Common Stock in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
77% more call options, than puts
Call options by funds: $390K | Put options by funds: $220K
76% more capital invested
Capital invested by funds: $5.68M → $9.99M (+$4.31M)
16% more funds holding
Funds holding: 32 → 37 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$631K |
| 2 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
+$407K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$397K |
| 4 |
MSU
Mizuho Securities USA
New York
|
+$393K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$323K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$109K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$86K |
| 3 |
SCM
Sio Capital Management
New York
|
-$56.3K |
| 4 |
Walleye Trading
New York
|
-$54.9K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.8K |
DMK Hedge Fund Activity: Q3 2016 in Review
37 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2016, worth a combined $9.99M — up 76% from $5.68M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMK positions and 5 closed out — a net gain of 5 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $631K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $109K sold.
- 37 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2016, up from 32 in Q2 2016.
- Funds reported $9.99M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2016, up 76% quarter-over-quarter.
- 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2016 and 5 closed out, a net change of +5 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2016 was Vanguard Group, an estimated $631K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2016 was Renaissance Technologies, an estimated $109K sold.
Based on aggregated 13F filings for Q3 2016.